Johanna Mercier, who serves as Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), completed a sale of 3,000 shares of common stock on April 15, 2026. The shares traded at $140.96 apiece, producing total gross proceeds of $422,880. Following the transaction, Mercier retained direct ownership of 128,779 shares in the company.
The sale was executed pursuant to a Rule 10b5-1 trading plan that Mercier established on February 20, 2025. That plan provides a prearranged framework under which the disposition occurred on the stated date and price.
These insider transaction details arrive at a time of operational and strategic activity at Gilead. The company announced a major scale-up in access to its twice-yearly injectable HIV prevention medicine lenacapavir. Under a planned funding initiative, the U.S. State Department, PEPFAR, and The Global Fund will invest to expand availability of the product by an additional 1 million people, targeting a cumulative reach of 3 million individuals in high-incidence, resource-limited countries by 2028.
Concurrently, Gilead has broadened its collaboration with Tempus AI to support oncology pipeline advancement. The expanded agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, which supplies datasets and analytical services intended for oncology research and development.
On the analyst front, Truist Securities adjusted its price target on Gilead to $155 from $152 and maintained a Buy rating. Truist expects Gilead’s first quarter of 2026 results to be in line with consensus, forecasting total revenue of $6.94 billion against a consensus estimate of $6.91 billion, and non-GAAP earnings per share of $1.84 versus a consensus EPS of $1.90.
RBC Capital has reiterated a Sector Perform rating on Gilead, calling attention to third-party prescription trends for Yeztugo and evaluating how those trends affect market performance for the product.
Context and implications
The insider sale itself was conducted under a standing trading plan and leaves the executive with a substantial direct holding. At the same time, the company is pursuing programmatic expansion of a HIV prevention therapy through investments by public health partners and is leveraging external AI capabilities to accelerate oncology research. Analysts remain engaged, with at least one firm raising its target and another signaling continued scrutiny of prescription dynamics for a key product.
Investors seeking detailed, company-level analysis can consult in-depth research resources referenced by the firm, which cover Gilead among a broad set of U.S. equities.